Geode Capital Management LLC Has $757,000 Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

Geode Capital Management LLC lifted its stake in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 17.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 605,191 shares of the company’s stock after purchasing an additional 88,183 shares during the quarter. Geode Capital Management LLC owned 0.94% of SELLAS Life Sciences Group worth $757,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Anson Funds Management LP bought a new stake in shares of SELLAS Life Sciences Group during the third quarter worth $992,000. XTX Topco Ltd acquired a new stake in shares of SELLAS Life Sciences Group during the 3rd quarter valued at $78,000. State Street Corp grew its position in SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after acquiring an additional 40,500 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $39,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ SLS opened at $0.95 on Friday. The stock has a market cap of $67.04 million, a P/E ratio of -1.38 and a beta of 2.41. SELLAS Life Sciences Group, Inc. has a 52-week low of $0.50 and a 52-week high of $1.72. The firm has a 50 day moving average price of $1.08 and a two-hundred day moving average price of $1.17.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.